SHINE Medical Technologies is dedicated to being the world leader in safe, clean, affordable production of medical tracers and cancer treatment elements. At SHINE, our highest priority is delivering a highly reliable, high-quality supply of the medical ingredients required by nearly 100,000 patients each day which are the backbone of over thirty medical procedures primarily used to detect and treat heart disease and cancer. By working around the clock, our goal is to ensure that medical tracers are there when patients need them most.

 

SHINE & Phoenix Combine for World Record

Phoenix and SHINE Achieve New World Record for Strongest Nuclear Fusion Reaction in a Steady-State System

Leading nuclear technology companies collaborating to help turn nuclear weapons into medicine and help a billion patients

Breakthrough has potential to transform medical isotope production, solve a global health care shortage, provide a stepping stone to cleaner, safer, more abundant energy

Piefer Awarded Honors by UW

JANESVILLE, Wis., Sept. 12, 2019 –SHINE Medical Technologies LLC today announced that its founder and CEO Greg Piefer has received the University of Wisconsin-Madison Department of Physics’ 2019 Distinguished Alumni Award.

Paul Ryan joins Board

JANESVILLE, Wis., Aug. 26, 2019 – SHINE Medical Technologies, LLC today announced the appointment of Paul D. Ryan to the company’s board of directors.

$15-million DOE/NNSA award for medical isotope

JANESVILLE, Wis., Aug. 9, 2019 – SHINE Medical Technologies LLC today announced it has received a $15-million award from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA). The award was made by the agency as part of its effort to establish a reliable, U.S.-produced supply of molybdenum-99 (Mo-99), the most commonly used medical isotope, without the use of highly enriched uranium.

SHINE files application with NRC

July 22nd, 2019 – JANESVILLE, WI – SHINE Medical Technologies LLC today announced that the company has filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes, including molybdenum-99 (Mo-99), iodine-131 and xenon-133, at its production facility in Janesville, WI. 

Technology Demonstration Validates Business Case

Phoenix Neutron Generator Completes Milestone Validating Output and Reliability June 19th, 2019 – Janesville, WI – SHINE Medical Technologies, a Janesville, WI medical isotope production company, announced the completion of an important milestone validating the SHINE...

Production Facility Groundbreaking

Production Facility Groundbreaking May 9th, 2019 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, broke ground today on their first...

SHINE Licenses Lu-177 Separation Process

Novel Separation Method Accelerates SHINE’s Path to Market for Cancer Treatment Isotopes May 15th, 2019 – Prague, Czechia – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin company dedicated to being the world leader in the safe, clean, affordable production of...

SHINE and Deerfield Close $150 Million Financing

SHINE and Deerfield Close $150 Million Financing SHINE AND DEERFIELD CLOSE $150 MILLION FINANCING COMMITMENT TO SUPPORT DIAGNOSTIC AND THERAPEUTIC MEDICAL ISOTOPE MANUFACTURING November 27, 2018 – New York, NY and Janesville, WI – SHINE Medical Technologies Inc....

Phoenix Delivers First Production Accelerator

Phoenix Delivers First Production Accelerator SHINE On Path to Become Leading Domestic Producer of Mo-99 Photo: SHINE CEO, Greg Piefer, standing with parts of the Phoenix first production unit accelerator, delivered to SHINE Building One on Monday. October 18th, 2018...